Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GRI Bio Inc GRI

Healthcare Biotechnology
GRI Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in... see more

Recent & Breaking News (NDAQ:GRI)

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

GlobeNewswire 2 days ago

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

GlobeNewswire 6 days ago

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

GlobeNewswire April 16, 2024

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

GlobeNewswire April 8, 2024

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire April 1, 2024

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

GlobeNewswire March 28, 2024

GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

GlobeNewswire March 14, 2024

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

GlobeNewswire March 4, 2024

GRI Bio Announces Pricing of $5.5 Million Public Offering

GlobeNewswire February 2, 2024

GRI Bio Announces Reverse Stock Split

GlobeNewswire January 26, 2024

GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis ("IPF")

GlobeNewswire December 5, 2023

GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT ("iNKT") Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis ("IPF")

GlobeNewswire November 27, 2023

GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 15, 2023

GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases

GlobeNewswire October 31, 2023

GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference

GlobeNewswire October 19, 2023

GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression

GlobeNewswire October 17, 2023

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference

GlobeNewswire October 11, 2023

GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions

GlobeNewswire October 5, 2023

September Is Pulmonary Fibrosis Awareness Month: Here's What One Company Is Doing To Develop A Treatment For This Deadly Disease

Accesswire September 29, 2023

GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 6, 2023